pm mfvt1
    • Main page
      • About journal
      • Articles. Working with contents
      • Editor-in-chief
      • Editorial Council
      • Editorial Board


      • For authors
      • Standards for formatting information
      • Reviewing
      • Politics editorial board
      • Ethics of journal publications


      • For advertisers
      • Subscription
      • About the Publishing House
      • Contact us
  • Estimation of the efficiency of allergen-specific immunotherapy in patients with atopic asthma and allergic rhinitis

    Редактор | 2019, Original articles, Practical medicine part 17 №6 (1) 2019 | 10 октября, 2019

    O.V. SKOROKHODKINA1, A.V. LUNTSOV2, S.A. ARKHIPOVA1

    1Kazan State Medical University, Kazan

    2Republican Clinical Hospital of the MH of RT, Kazan

     Contact:

    Skorokhodkina O.V. ― MD, Head of the Department of Clinical Immunology and Allergology

    Address: 49 Butlerov Str., Kazan, Russian Federation, 420012, tel. +7-917-392-50-45, e-mail: olesya-27@rambler.ru 

    Objective ― to evaluate the comparative efficacy and safety of allergen-specific immunotherapy in patients with allergic rhinitis and bronchial asthma.

    Material and methods. Medical documentation was analyzed of patients with validated questionnaires and scales during the application of allergen-specific immunotherapy for 3 years in 111 patients with allergic rhinitis and bronchial asthma. Statistical processing of the data was carried out using the software package Statistica 10.0.

    Results. According to the results of the analysis of validated questionnaires, the clinical efficacy parameters of SCIT and SLIT after a year, two and three years of therapy, were comparable. At the end of the 3rd year of SCIT, the average score on the CSMS scale for patients with AR was 1.25, and SLIT was 0 points. The average CARAT10 score in patients with a combination of AD and AR after 3 years of therapy significantly increased both in the group of patients receiving SCIT and SLIT. When conducting SCIT, local adverse reactions were observed in 5 patients (4.5%), and when using SLIT in 3 patients (less than 1%).

    Conclusion. Efficacy of SCIT and SLIT in patients of both groups was comparable (p>0.05). However, the best tolerance of SLIT and the possibility of it being carried out outside the treatment and prophylactic activity increased the patients’ compliance.

    Key words: bronchial asthma, allergic rhinitis, allergen-specific immunotherapy.

    (For citation: Skorokhodkina O.V., Luntsov A.V., Arkhipova S.A. Estimation of the efficiency of allergen-specific immunotherapy in patients with atopic asthma and allergic rhinitis. Practical medicine. 2019. Vol. 17, № 6 (part 1), P. 44-48)

    REFERENCES

    1. Khaitov R.M., Il’ina N.I. Klinicheskie rekomendatsii. Allergologiya i klinicheskaya immunologiya [Clinical recommendations. Allergology and clinical immunology]. Moscow: GEETAR-Media, 2019. Pp. 302-316.
    2. Veen W., Wirtz O., Globinska A., Akdis M. Novel mechanisms in immune tolerance to allergens during natural allergen exposure and allergen-specific immunotherapy. Current Opinion in Immunology, 2017, 48, pp. 74-81.
    3. Pavlova K.S., Kurbacheva O.M., Galitskaya M.A., Smirnov D.S. Actual ideas about the mechanisms of allergen-specific immunotherapy, potential markers of effectiveness and ways to improve. Rossiyskiy allergologicheskiy zhurnal, 2017, no. 4-5, pp. 5-17 (in Russ.).
    4. Cavkaytar O., Akdis C., Akdis M. Modulation of immune responses by immunotherapy in allergic diseases. Current Opinion in Pharmacology, 2014, 17, pp. 30-37.
    5. Pfaar O., Demoly P., Gerth van Wijk R., et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy, 2014, 69, pp. 854-867.
    6. Nenasheva N.M. Atopic bronchial asthma: the role of allergen-specific immunotherapy. Rossiyskiy allergologicheskiy zhurnal, 2015, no. 6, pp. 54-67 (in Russ.).
    7. Mauri C., Bosma A. Immune regulatory function of B cells. Annual Review of Immunology, 2012, 30, pp. 221-241.
    8. Kurbacheva O.M., Pavlova K.S., Galitskaya M.A. Allergen-specific immunotherapy. An analytical review of modern international and domestic positional documents. Rossiyskiy allergologicheskiy zhurnal, 2017, no. 1, pp. 24-32 (in Russ.).
    9. GINA 2019, available at: www.ginasthma.org
    10. Lombardi C., Melli V., Incorvaia C. and Ridolo — Lombardi E. et al. Pharmacoeconomics of sublingual immunotherapy with the 5 grass pollen tablets for seasonal allergic rhinitis. Clinical and Molecular Allergy, 2017, 15, 5.
    11. Glants S. Mediko-biologicheskaya statistika [Biomedical statistics]. Moscow: Praktika, 1998. 459 p.
    12. Rebrova O.Yu. Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm Statistica [Statistical analysis of medical data. Application of the software package Statistica]. Moscow: MediaSfera, 2002. 200 p.
    13. Khafiz’yanova R.Kh., Burykin I.M., Aleeva G.N. Matematicheskaya statistika v eksperimental’noy i klinicheskoy farmakologii [Mathematical statistics in experimental and clinical pharmacology]. Kazan: Meditsina, 2006. 374 p.
    14. Agache I., Akdis C.A., Chivato T., et al. White Paper on Research, Innovation and Quality Care. Published by the European Academy of Allergy and Clinical Immunology, 2018.

    Метки: 2019, A.V. LUNTSOV, allergen-specific immunotherapy, allergic rhinitis, bronchial asthma, O.V. SKOROKHODKINA, Practical medicine part 17 №6 (1) 2019, S.А. АRKHIPOVA

    ‹ Possibilities of a multidetector computer tomography (MDCT) angiography of heart and coronary arteries at ambulatory stage of diagnostics of an ischemic heart disease  Disability in patients with type 1 Chiari malformation ›
    • rus Версия на русском языке


      usa English version site


      Find loupe

      

    • PARTNERS

      пов  logonew
    «Для
    Practical medicine. Scientific and practical reviewed medical journal
    All rights reserved ©